

Special Issue

Utilizing Multi-Omics to Investigate Neurodegenerative Disorders

Message from the Guest Editor

This Special Issue of *Genes* invites original research articles, reviews, and methodological advancements focused on applying multi-omics approaches to investigate neurodegenerative disorders. We encourage submissions that explore the following topics:

Integrative analyses linking genetic, transcriptomic, and proteomic data to uncover molecular signatures of neurodegeneration.

Biomarker discovery and validation using omics datasets.

Pathway enrichment and network-based analyses to identify dysregulated biological processes.

Novel computational approaches for multi-omics data integration and interpretation.

Studies investigating the role of genetic variants and regulatory mechanisms in disease progression.

By bringing together interdisciplinary research, this Special Issue aims to foster collaboration and advance our understanding of the complex biology underlying neurodegenerative diseases. We look forward to receiving contributions that push the boundaries of multi-omics research and offer insights into potential therapeutic strategies.

Guest Editor

Dr. Muhammad Ali

School of Medicine, Washington University, St. Louis, MI 63110, USA

Deadline for manuscript submissions

closed (25 March 2026)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/235391

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))